BCD to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery
ConditionUremia
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorGang Chen
About this trial
This study intends to measure the ED95 of remimazolam-assisted sedation in arteriovenous fistula creation by BCD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18-65 years old (including borderline values).
Elective surgical patients under local anaesthesia for operation of AVF
Voluntary participation in this study and signing of informed consent.
American Society of Anesthesiologists (ASA) classification < Grade IV.
Disqualifiers
hypersensitivity to remimazolam or benzodiazepines.
patients with severe cardiac, pulmonary, neurological diseases or liver failure. -- Preoperative use of sedative drugs, anticonvulsants, etc.
patients who cannot cooperate with postoperative recovery or follow-up.
vulnerable groups, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, illiterates, etc.
Trial design
Design model
Single group
Treatments tested in this trial
remimazolam sedation
Drugremimazolam sedation
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: remimazolam groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
ED95
the dose of Remimazolam that provides satisfactory sedation in 95% of patients.
Time frame
1 dayLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Gang Chen
Lead sponsor
Sir Run Run Shaw Hospital
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: